Key result
A novel radioimmunoassay system using antiserum (I-3) with a homologous tritium-labeled antigen demonstrated cross-reactivity with digoxin metabolites matching their cardio-activities, indicating utility for therapeutic drug monitoring.
Answers are grounded in this paper and cite their sources.
A novel radioimmunoassay using antiserum (I-3) and a homologous tritium-labeled antigen accurately reflects the pharmacological activity of digoxin and its metabolites, making it highly suitable for therapeutic drug monitoring.
The specificities of antisera against digoxin C-3' or C-3'' hemisuccinate-bovine serum albumin (BSA) conjugate were assessed by cross-reactivity studies with digoxin metabolites by radioimmunoassay (RIA) using the homologous and the site heterologous tritium-labeled antigens. One of the tracers used was digoxin 3'-hemisuccinyl-[3H]-leucine; the other was digoxin 3''-hemisuccinyl-[3H]-leucine, which had been prepared from digoxin 3''-hemisuccinate. When the tracer with [3H]-leucine at the C-3' position was used, antisera (I-1, I-3) elicited by digoxin 3'-hemisuccinate-BSA conjugate showed the following cross-reactivity: digoxigenin bisdigitoxoside (0.34%, 76%), digoxigenin monodigitoxoside (0.11%, 65%), digoxigenin (0.02%, 26%) and dihydrodigoxin (9.4%, 1.2%). However, when using the homologous antigen, antiserum (I-1) was highly specific against the digitoxose chain. When the site heterologous antigen, digoxin 3''-hemisuccinyl-[3H]-leucine was combined, this antiserum showed high cross-reactivity to digoxin degradation products. This digoxin RIA using antiserum (I-1) with the homologous antigen measures unmetabolized digoxin. On the other hand, the RIA system using antiserum (I-3) with the homologous antigen had cross-reactivity with the metabolites in accordance with their relative cardio-activities, so this system would be useful in therapeutic drug monitoring of digoxin.
No takes yet. Share an insight, caveat, or question.
Ikeda et al. (2005) studied Therapeutic drug monitoring of digoxin. Novel anti-digoxin antisera in radioimmunoassay vs. Other antisera and commercial immunoassays was evaluated on Cross-reactivity with digoxin metabolites. A novel radioimmunoassay system using antiserum (I-3) with a homologous tritium-labeled antigen demonstrated cross-reactivity with digoxin metabolites matching their cardio-activities, indicating utility for therapeutic drug monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: